Marker Therapeutics, Inc.
MRKR
$1.20
$0.065.26%
| Weiss Ratings | MRKR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | MRKR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | MRKR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.79 | |||
| Price History | MRKR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.25% | |||
| 30-Day Total Return | -22.58% | |||
| 60-Day Total Return | -63.53% | |||
| 90-Day Total Return | -62.38% | |||
| Year to Date Total Return | -62.26% | |||
| 1-Year Total Return | -72.48% | |||
| 2-Year Total Return | 53.81% | |||
| 3-Year Total Return | -73.69% | |||
| 5-Year Total Return | -93.62% | |||
| 52-Week High % Change | -80.97% | |||
| 52-Week Low % Change | 3.64% | |||
| Price | MRKR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $5.99 | |||
| 52-Week Low Price | $1.10 | |||
| 52-Week Low Price (Date) | Apr 01, 2025 | |||
| 52-Week High Price (Date) | Jul 18, 2024 | |||
| Valuation | MRKR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 12.21M | |||
| Enterprise Value | -6.98M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.10 | |||
| Earnings Per Share Growth | 0.64% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.89 | |||
| Price/Book (Q) | 1.37 | |||
| Enterprise Value/Revenue (TTM) | -1.29 | |||
| Price | $1.20 | |||
| Enterprise Value/EBITDA (TTM) | 3.12 | |||
| Enterprise Value/EBIT | 0.69 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | MRKR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 8.92M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | MRKR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 713 400 6400 | |||
| Address | 9350 Kirby Drive Houston, TX 77054 | |||
| Website | markertherapeutics.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | MRKR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -188.93% | |||
| Profit Margin | -179.71% | |||
| Management Effectiveness | MRKR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -41.92% | |||
| Return on Equity | -- | |||
| Income Statement | MRKR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 5.40M | |||
| Total Revenue (TTM) | 5.40M | |||
| Revenue Per Share | $0.61 | |||
| Gross Profit (TTM) | -5.60M | |||
| EBITDA (TTM) | -2.24M | |||
| EBIT (TTM) | -10.19M | |||
| Net Income (TTM) | -9.70M | |||
| Net Income Avl. to Common (TTM) | -9.70M | |||
| Total Revenue Growth (Q YOY) | 647.67% | |||
| Earnings Growth (Q YOY) | 22.60% | |||
| EPS Diluted (TTM) | -1.10 | |||
| EPS Diluted Growth (Q YOY) | 23.53% | |||
| Balance Sheet | MRKR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 9.00M | |||
| Cash Per Share (Q) | $1.01 | |||
| Total Current Assets (Q) | 10.91M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 7.45M | |||
| Current Ratio (Q) | 3.153 | |||
| Book Value Per Share (Q) | $0.83 | |||
| Total Assets (Q) | 10.91M | |||
| Total Current Liabilities (Q) | 3.46M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 3.46M | |||
| Total Common Equity (Q) | 7.45M | |||
| Cash Flow | MRKR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 0.00 | |||
| Cash from Financing (TTM) | 100.50K | |||
| Net Change in Cash (TTM) | -8.47M | |||
| Levered Free Cash Flow (TTM) | -5.25M | |||
| Cash from Operations (TTM) | -8.57M | |||
